SOURCE: Organetix, Inc.

August 30, 2005 08:30 ET

Organetix Retains ROI Group Associates as Investor Relations Counsel

Organetix Pursuing Fast-track Strategy to Introduce Bioceutical Targeting Hepatitis C, Cirrhosis, Other Diseases of the Liver and to Assist Chemotherapy Patients

Company Has Exclusive Worldwide License for Proprietary Formula

NEW YORK, NY -- (MARKET WIRE) -- August 30, 2005 --Organetix, Inc. (OTC BB: OGTX) www.organetixinc.com, a developer of nutraceuticals and bioceuticals initially targeting Hepatitis C, Cirrhosis, other diseases of the human liver, and to assist chemotherapy patients, announced today it has retained ROI Group Associates, Inc., New York, NY, as its investor relations counsel.

In announcing the initiative, Brad Clarke, President and Chief Executive Officer of Organetix, said, "Organetix is a biotechnology company that has the exclusive worldwide license for a nutraceutical formula, referred to as A4+L, a proprietary medical discovery targeting the human liver. The company is currently pursuing a fast-track strategy that addresses several critical human medical conditions that represent substantial markets, including Hepatitis C, Cirrhosis and other related diseases of the liver and to assist patients being treated with chemotherapy. We are seeking to establish a pipeline of patented bioactive compounds and their unique formulas and processes from plants having a successful history of medicinal use. As Organetix gains momentum going forward management believes this is the time to increase the visibility and awareness of the company in the investment community. We have retained ROI Group Associates to implement a targeted investor relations program in order to enhance Organetix recognition to institutional and retail investors, and actively communicate with our shareholder base. Their experience developed by working with several biotechnology companies specifically, and with smaller capitalization equities generally, makes ROI Group especially attractive."

Mr. Clarke continued, "We believe Organetix will continue to make meaningful progress towards developing a robust pipeline of nutraceuticals and bioceuticals as foundations for new and exciting drugs based on plant-based medicines. We will continue to research, develop and patent these bioactive compounds that address the health of millions of people worldwide. We believe this is the appropriate time for Organetix to be recognized as an emerging leader in our industry, and ROI Group can help us achieve that goal."

Robert Giordano, President of ROI Group Associates, commented on its appointment, "We are excited to work with Organetix. Their nutraceutical and bioceutical markets are vital to the health of many millions of patients as well as substantial in terms of revenues. Management of Organetix is working diligently to complete a major financing and to take products to market as rapidly as possible. They have such an exciting story to tell the financial community. ROI has demonstrated considerable success in developing strategies and delivering investor relations programs for various biotechnology and healthcare companies, especially tailored to the requirements of smaller capitalization growth companies, and we anticipate the same with Organetix."

About Organetix, Inc.

Organetix is a biotechnology company that has the exclusive worldwide license for the formula of a proprietary medical discovery relating to the liver. Organetix will seek to patent, research, develop, produce and sell this proprietary liver product initially as a nutraceutical. This liver product has been used specifically to treat patients with Hepatitis C. Limited research shows it is regenerating liver tissue thus allowing the liver to begin functioning again despite years of damage from the virus. Therefore, this product may be useful for treating all liver disorders including Cirrhosis and may someday eliminate most liver transplants. Much like insulin being used for diabetes, this proprietary liver product does not cure Hepatitis C but has the capability of regenerating the liver.

The nutraceutical liver product, A4+L, will directly compete in a billion dollar market that currently exists around the world.

Organetix will specialize in researching, developing and patenting bioactive compounds and their unique formulas and processes from plants having a unique history of medicinal use. We feel that nutraceuticals and bioceuticals are the foundations for the new and exciting drugs to be discovered in the 21st Century. Additional information on Organetix is available on its web site www.organetixinc.com.

Organetix trades on the OTC BB under the symbol: OGTX.

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events, or otherwise.

Contact Information

  • Company Contact
    Corporate Office:
    Brad Clarke, President and CEO
    Phone: 212.758 4454 ext # 224
    Fax: 403.264.3310
    Email: Email Contact

    Organetix Inc.
    15th Floor
    405 Park Avenue
    New York, NY 10022
    USA

    Investor Relations Contact:
    Michael Dodge / Robert Giordano
    ROI Group Associates, Inc.
    Phone: 212.495.0200 x 17
    Email: Email Contact / Email Contact
    www.roiny.com